Few factors have been identified that can be used to predict response of patients with eosinophilic esophagitis (EoE) to topical steroid treatment. We aimed to determine whether baseline clinical, endoscopic, histologic, and molecular features of EoE can be used to predict histologic response.
T opical corticosteroids are a commonly used pharmacologic therapy for the management of eosinophilic esophagitis (EoE). 1, 2 Both swallowed fluticasone and budesonide have been shown to be effective in decreasing esophageal eosinophilia 3 ; however, symptom response has been more heterogeneous. [4] [5] [6] [7] Even in terms of histologic response, some studies have shown that nearly 50% of EoE patients may not respond to steroid therapy. [8] [9] [10] [11] Some possible reasons for nonresponse include patient noncompliance, inadequate treatment dosing, suboptimal steroid formulation or esophageal contact time, and a possible steroidrefractory phenotype of EoE. 5, 11, 12 Having the ability to identify which patients are less likely to have a histologic response to steroids would have important prognostic implications. Despite the need for better risk-stratification tools to assess treatment response in EoE, there are few data identifying predictors of topical steroid response. One retrospective study showed the need for baseline dilation and molecular factors, such as decreased levels of mast cells and eotaxin-3 predicted nonresponse in EoE adults treated with topical fluticasone or budesonide. 13 Phenotypic differences have also been implicated in predicting treatment response. Those with a fibrostenotic phenotype and narrowed esophagus are less likely to respond to topical steroids. 12 Gene analysis has shown that polymorphisms in the transforming growth factorb1 gene are associated with steroid resistance in EoE. 14 Similarly, an EoE gene array comprising of 94 genes, the EoE diagnostic panel, showed a subset of genes were differentially expressed in nonresponders to fluticasone. 4 Identifying predictors of treatment response to topical steroids is key to delivering effective and individualized disease management, but there are inadequate prospective data assessing them, and the potential predictors noted previously are not yet routinely used in clinical care. Therefore, the aim of this study was to determine whether baseline (pretreatment) clinical, endoscopic, histologic, and molecular features of EoE can be used to predict histologic response to topical steroids in adult EoE patients.
Methods

Study Design, Patients, and Data Collection
This was an analysis of data and samples collected during a prospective study conducted at the University of North Carolina from 2009 to 2015. 15 Participants were consecutive adults scheduled to undergo outpatient upper endoscopy for symptoms of esophageal dysfunction. Participants were enrolled before undergoing endoscopy and were excluded if they had a known diagnosis of EoE or eosinophilic gastrointestinal disorder, esophageal varices, prior esophageal surgery, bleeding or on anticoagulation, medical instability, or multiple comorbidities.
Eligible cases were diagnosed with EoE per consensus guidelines, 1, 16 with at least 15 eosinophils per high-power field (eos/hpf) on esophageal biopsy after an 8-week course of high-dose proton pump inhibitor (PPI) therapy and exclusion of alternate causes of esophageal eosinophilia. Those with PPI-responsive esophageal eosinophilia were excluded from the present analysis. This is because at the time the study was designed and conducted, failure of a PPI trial remained necessary for EoE diagnosis. 1, 16, 17 Because we previously demonstrated the clinical and molecular similarities between EoE and PPI-responsive esophageal eosinophilia, 18, 19 and because the present study protocol focused on predicting steroid response, steroids were not routinely offered to PPI-responsive esophageal eosinophilia patients. The study was approved by the University of North Carolina Institutional Review Board. Clinical data were prospectively collected using standardized case report forms as previously outlined. 15, 20, 21 Atopic and food allergy history was obtained by self-report. All endoscopic biopsies were obtained per research protocol. Two biopsies from the proximal, 1 from the mid, and 2 from the distal esophagus were collected. Gastric and duodenal biopsies were collected to exclude alternate eosinophilic disorders. From each biopsy, the maximum eosinophil count (eos/hpf) was quantified using a microscopic field size of 0.24 mm 2 and per our previously described method.
22,23
Topical Steroid Treatment and Definitions of Histologic Response
EoE cases were treated per a standard clinical protocol with an 8-week course of either oral viscous budesonide (1 mg twice a day) or fluticasone from a multidose inhaler (880 mg twice a day). 24 Repeat esophagogastroduodenoscopy with esophageal biopsies was performed at the end of the 8-week treatment, and follow-up clinical and symptom data were also collected.
The primary outcome of this study was histologic response. There is debate in the literature related to the "correct" histologic response threshold in EoE. [25] [26] [27] Varying eosinophil cutpoints have been used in different studies, 24 and an arbitrary threshold may obscure response data, making it harder to differentiate predictive factors. Therefore, 2 separate histologic response definitions were used in this study. For the first, we defined response as <15 eos/hpf and What You Need to Know Background Few baseline clinical, endoscopic, histologic, and molecular predictors of histologic response to topical steroids have been identified in eosinophilic esophagitis. Knowledge of independent predictors of treatment response would help target clinical care.
Findings
A model comprising of five factors predicted complete response (<1 eos/hpf) with AUC of 0.88 compared to those with clear nonresponse (<50% decrease in baseline eos/hpf), with no differences in a gene expression panel measured at baseline.
Implications for patient care
Patients at high risk for nonresponse to topical steroids could be identified early so that alternative therapies can be used.
nonresponse as !15 eos/hpf on post-treatment esophageal biopsies. For the second, response was defined as "complete" responders comprising of those with <1 eos/ hpf and "complete" nonresponders as those with <50% decrease in eosinophil counts from baseline following treatment, and those who did not fit these criteria were omitted. This second definition allowed us to perform a sensitivity analysis by comparing extremes of the response threshold, "complete" responders versus "complete" nonresponders, to determine if additional predictors can be identified.
Gene Expression Determination
After completion of patient enrollment, gene expression determination was performed using a single RNAlater-preserved biopsy from the mid-esophagus (approximately 10 cm above the gastroesophageal junction), which had been snap frozen and stored at -80 o C immediately after collection (Miraca Life Sciences, Phoenix, AZ), as previously reported. 28, 29 After thawing of frozen specimens, RNA was extracted from homogenized tissue using RNeasy Mini Extraction kit (Qiagen, Valencia, CA). An acceptable concentration was defined as 16.5 ng/mL of RNA for a total of 500 ng. From the extracted RNA, cDNA synthesis was performed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) with polymerase chain reaction performed on ABI 9700 (Applied Biosystems, Foster City, CA). The cDNA and TaqMan Universal Master Mix II, no UNG (Life Technologies, Carlsbad, CA) were loaded onto Taqman TLDA cards. These cards were preloaded in a 384-well format with the 94-gene EoE diagnostic panel previously developed for EoE 30 and 2 housekeeping genes (GAPDH and 18S). Polymerase chain reaction was performed on Quant Studio 7 (Life Technologies) to determine the gene expression levels.
Gene expression levels were measured as threshold cycles (CT) with a value <30 considered acceptable. A summary score was calculated using a previously established algorithm 30 by subtracting the CT value of the housekeeping gene from the CT value of each gene of interest to acquire the DCT. The absolute values of the normalized gene CT values were summed for each gene in the gene expression panel.
Statistical Analysis
Clinical, endoscopic, histologic features, and overall gene scores were compared between histologic responders and nonresponders using chi-square test for categorical variables, and Student t test or Wilcoxon rank sum test for continuous variables as appropriate. Expression of individual genes was compared between responders and nonresponders, using an unpaired 2-sided Student t test and false detection rate of 0.10 to account for multiple testing. Sensitivity analyses using alternative histologic response definitions as described previously were also performed.
Multivariate logistic regression was performed to assess predictors of histologic response to topical steroids. Predictive risk factors for steroid response on bivariate comparison with P < .10 were included in the initial model, taking into account collinear and confounding variables, which was then subsequently reduced until all factors were significant at the P < .05 level. The model was further simplified to include only the variables that were significantly contributing to the model using likelihood ratio testing. Receiver operating characteristic curves were constructed and areas under the curve (AUC) were calculated to measure the discrimination of the model and goodness-of-fit testing was performed to measure the calibration of the model. Missing data were excluded from the analysis.
Results
Patient Characteristics
There were 97 EoE cases with complete pretreatment and post-treatment clinical, endoscopic, and histologic data that were included in this analysis; 91 of these patients had gene expression data available. Approximately 60% of the sample were men and >90% were white; full demographic characteristics have been previously reported. 28 Of this group, 85 (88%) were treated with budesonide (mean dose, 2200 mg/day) and 12 (12%) were treated with fluticasone (mean dose, 1700 mg/day).
Predictor Analysis With Responder Definition of <15 Versus !15 Eosinophils Per High-Power Field
There were 59 (61%) histologic responders and 38 (39%) nonresponders. There was no difference in baseline mean peak eosinophil counts between responders and nonresponders (129 AE 113 vs 143 AE 135; P ¼ .58). There were few differences in clinical, endoscopic, or histologic features between responders and nonresponders (Table 1) . Responders tended to have more atopy (82% vs 66%; P ¼ .08), less esophageal edema (46% vs 66%; P ¼ .05), and less epithelial spongiosis (80% vs 95%; P ¼ .05). Presence of baseline stricture (45% vs 17%; P < .01) and the need for esophageal dilation (47% vs 20%; P < .01) at baseline was significantly more common in nonresponders compared with responders. In multivariate analysis, the need for baseline dilation was the only independent predictor of histologic nonresponse (adjusted odds ratio, 0.30; 95% confidence interval, 0.10-0.89).
In the molecular analysis, there was no difference in mean baseline gene scores between responders and nonresponders (203 AE 136 vs 185 AE 143; P ¼ .56).
There was also no difference in baseline gene expression patterns ( Figure 1A ) or in expression of individual genes (Supplementary Table 1 Of 63 EoE cases who met this definition, there were 34 (54%) responders and 29 (46%) nonresponders. A total of 85% (n ¼ 29) of the responders and 93% (n ¼ 27) of the nonresponders were treated with budesonide. Mean steroid doses between the responders and nonresponders were similar: budesonide (2000 mg vs 2340; P ¼ .05) and fluticasone (1630 vs 1760 mg; P ¼ .71) ( Table 2 ). Responders were older (44 vs 34 years; P < .01) and had more food allergies (50% vs 19%; P ¼ .02). Presence of baseline stricture (48% vs 15%; P < .01), narrowing (45% vs 21%; P ¼ .04), need for baseline dilation (52% vs 24%; P ¼ .02), and hiatal hernia (21% vs 6%; P ¼ .08) were all more common in nonresponders.
In multivariable logistic regression, older age and having food allergies independently predicted increased odds of complete response, whereas baseline dilation, presence of edema/decreased vascularity on endoscopy, and presence of hiatal hernia on endoscopy independently predicted decreased odds of complete response (Table 3) . Using these 5 factors, a predictive model had sensitivity of 85%, specificity of 78%, and accuracy of 82% in discriminating complete responders from clear nonresponders. Receiver operating characteristic curve analysis showed an AUC of 0.88, and the chi-square test of goodness-of-fit had P ¼ .90, indicating a good fit (Figure 2) .
In the molecular analysis, there was no difference in mean baseline gene scores between responders and nonresponders (192 AE 137 vs 196 AE 151; P ¼ .92). There was also no difference in baseline gene expression patterns ( Figure 1B ) or in expression of individual genes from a limited gene expression panel (Supplementary  Table 1 ).
Discussion
In this prospective study of EoE cases treated with an 8-week course of a topical steroid, 46%-61% had histologic response based on the definition used. When a more traditional response (<15 eos/hpf) and nonresponse (!15 eos/hpf) definition was applied, 26, 27 other than the need for baseline dilation, there were no pretreatment features that independently predicted response to steroid therapy. When alternate response (<1 eos/hpf) and nonresponse (<50% decrease in baseline eos/hpf) definitions were used, independent Other histologic data available for n ¼ 60 of total sample; lamina propria fibrosis (n ¼ 39). Missing data were excluded from analysis. Other histologic data available for n ¼ 60 of total sample; lamina propria fibrosis (n ¼ 39). Missing data were excluded from analysis.
predictors of response were older age and history of food allergies, and predictors of nonresponse were presence of edema or hiatal hernia endoscopically, and the need for baseline dilation. This model showed good discrimination (AUC ¼ 0.88) between complete steroid responders and the clear nonresponders. However, no differences in baseline gene expression, either measured by the summary gene score or by differential expression between individual genes, were noted between the groups regardless of the response definition. Nonresponders were found to have a significantly higher prevalence of baseline strictures and esophageal narrowing. Because the presence of strictures and narrowing were highly correlated with the need for baseline dilation, dilation was used as a surrogate marker for those with a severe fibrostenotic phenotype and was included in the multivariable model. Need for baseline dilation was a common predictor identified using either of the treatment response definitions. Dilation was previously found to be a predictor of nonresponse in a retrospective cohort of EoE patients from our center 13 and in preliminary data from a separate study. 31 A steroid-resistant phenotype of EoE, an extreme narrowcaliber esophagus, has also been described. 12 In the context of these studies that show that the need for dilation is associated with a decreased likelihood of response to topical steroids, it is unclear whether swallowed fluticasone or oral viscous budesonide do not provide effective drug delivery in those with strictures or if fibrostenotic disease represents a more severe disease state that is treatment refractory. Data supporting the theory of steroid resistance as a mechanism for nonresponse include differential gene expression signatures 4 and a single-nucleotide polymorphism in transforming growth factor-b1.
14 Additionally, increased levels of esophageal FK506-binding protein 5 mRNA levels have been noted in patients treated with fluticasone, indicating that swallowed steroid therapies can directly affect gene expression in EoE and can potentially prognosticate treatment response. 32 Unfortunately, in this study, we did not find differences in gene expression profiles between the responders and nonresponders, and specifically did not see any difference in the previously reported gene signature, or in transforming growth factor-b or FK506-binding protein 5 expression levels. 4, 14, 32 However, we did not perform patient genotyping or single-nucleotide polymorphism testing. In our study, history of food allergies was associated with increased odds of complete response (<1 eos/hpf). Two prior studies support this finding and showed increased levels of mast cells in esophageal tissue in steroid-responsive patients. 13, 33 However, other studies have shown partial or complete nonresponse to steroids in those with history of allergies. 34, 35 Finally, there are also studies that have failed to identify any predictors of response. 36, 37 Why might the search for predictors of response be so difficult? One reason could be in the choice of treatment response definition. Because the EoE diagnosis definition is !15 eos/hpf, some studies define treatment response as <15 eos/hpf and nonresponse as !15 eos/ hpf, and this is now supported by analyses showing symptom and endoscopic improvements at this threshold. 26, 27 However, with this definition, a patient who has a decrease in eosinophil count from a baseline of 100 eos/hpf to 15 eos/hpf after treatment is considered a nonresponder despite having an 85% decrease in the eosinophil counts. This raises the question of whether there is value in assessing treatment response as a proportional change from baseline eosinophil count, rather than as a discrete cutpoint. Therefore, in this study, we tested an alternate treatment response definition to compare the extremes on the response spectrum, which resulted in identification of a larger set of clinical predictors, but did not change the results of the molecular analysis. However, the primary limitation of the model derived from this approach is that it cannot be applied to the group of intermediate responders. Other study limitations include lack of formal allergy testing and having a standardized protocol for steroid administration, which is more reflective of a real-world practice. A final limitation is the focus on histologic response. We Figure 2 . ROC for a multivariable predictive model of complete histologic response (defined at <1 eos/hpf). The AUC is reported.
acknowledge that symptom, endoscopic, and other important endpoints need to be assessed, and are a focus of future research. However, at the time this study was designed and conducted, these metrics were either not in existence or did not have clearly defined response thresholds. Despite these limitations, the study has multiple strengths. This was a large prospective cohort using a rigorous study design, data collection protocols, and sample handling. In addition, we tested multiple treatment response definitions to demonstrate differences in results, and we were able to incorporate molecular analyses. The findings of this study support additional data linking severe fibrostenotic disease with steroid resistance.
In conclusion, we showed that baseline dilation was the only predictor of response to topical steroid treatment at a histologic response threshold of <15 eos/hpf. No other clinical or molecular features of EoE predicted response at this level. However, a model comprised of 5 factors was able to predict complete response (<1 eos/ hpf) with AUC of 0.88 compared with the EoE group with clear nonresponse (<50% decrease in baseline eos/hpf), which, if validated, suggests a high degree of clinical utility. Patients who are at high risk for nonresponse to topical steroids could be identified early so that alternative therapies or delivery formulations can be used. 38 There may also be a need to assess response using more nuanced definitions because of the limitations of using distinct eosinophil cutpoints, and this should be taken into account in future studies aimed at identifying predictors of histologic response.
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